Karen Fallen, Touchlight CEO

Pfiz­er lines up ac­cess to 'dog­gy­bone DNA' in man­u­fac­tur­ing of mR­NA vac­cines, gene ther­a­pies and more

As Pfiz­er builds a whole fran­chise of ge­net­ic prod­ucts on the cor­ner­stone of its mR­NA Covid-19 vac­cine, it’s test­ing out a new way to man­u­fac­ture them.

Touch­light, which has been net­ting deals in the ever-ex­pand­ing and com­pet­i­tive DNA man­u­fac­tur­ing space, has inked a non-ex­clu­sive patent li­cense agree­ment with Pfiz­er. The deal gives Pfiz­er rights to Touch­light’s en­zy­mat­ic DNA, called dog­gy­bone DNA, or dbD­NA, to man­u­fac­ture and com­mer­cial­ize mR­NA-based vac­cines and ther­a­peu­tics as well as DNA vac­cines and gene ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.